One clinical trial site has been activated with patient enrollment expected to total six to eight participants and begin during April. Phase 1 Study Design The objectives of this Phase 1 single dose ...

Aspire Biopharma (ASBP) announced initiation of its Phase 1 single- center clinical study of its lead therapeutic candidate, an oral ...

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one monthA second pediatric ...

- CYT-108 is a recombinant protease inhibitor therapy with potential disease-modifying effects - JUPITER, Fla., April 1, 2025 /PRNewswire/ -- Cytonics, an early-stage biopharmaceutical company ...

Humacao, Puerto Rico Saturday, April 12, 2025, 11:00 Hrs [IST] ...